Article and Video CATEGORIES
I'm very happy to present an audio interview with Dr. Eric Vallières, an excellent thoracic surgeon and Surgical Director of the Lung Cancer Program at Swedish Cancer Institute. Within the lung cancer community, he actually happens to be among the most well known thoracic surgeons in the country and even world, and he has a major expertise in the integration of chemotherapy and other systemic therapies for early stage lung cancer. He was also one of the first people to welcome me enthusiastically into the lung cancer world when I was still completing my oncology training, and we've worked closely together for the last decade.
Dr. Vallières will be providing a lot of very helpful discussion on the surgical perspective, but this initial podcast focuses on the basics of surgery for lung cancer. It cover the initial pre-operative work-up, general aspects of the different types of surgery for lung cancer, and some on potential complications of surgery for lung cancer.
[powerpress]
This interview is being presented in two formats. It's an audio interview, but there are figures that appear, synchronized with the discussion. The link with the audio is just below, and the podcast link to the vidio version is at the bottom.
Intro to Surgery for LC Audio Podcast mp3
The links to the pdfs for the figures and transcript are below:
Intro to Surgery for LC Images
Intro to Surgery for LC Transcript
Dr. Vallières is a remarkably thorough and patient teacher. I hope you find it a helpful program.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…